ClinicalTrials.gg
CompletedNCT00532129Updated Apr 6, 2016Results posted

A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia.

A Phase 2 interventional study of Rituximab and Chlorambucil in Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche. Completed at 12 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-06.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 12 under way, 4 of them phase 3. Rituximab · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
31st of 189
100 · median 39
Started
2007
with 10 others
Phase 2
119 of 197
1 open now
Registered
83rd of 197
by date
Lead sponsor
9 of 197
Hoffmann-La Roche

Among the 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 31st largest by enrollment of the 189 interventional ones that give a count, is one of 11 that started in 2007, is one of 119 in phase 2, and was the 83rd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,038 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

3 of the 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies testing rituximab in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This single arm study will assess the safety and effect on response rate of a combination of rituximab and chlorambucil in previously untreated participants with B-cell chronic lymphocytic leukemia. Participants will receive 6 monthly cycles of combination treatment, followed by up to 6 cycles of chlorambucil alone. Rituximab will be administered on Day 1 of each cycle, at a dose of 375 milligrams per square meter (mg/m\^2) intravenously (IV) in Cycle 1, and 500 mg/m\^2 in subsequent cycles, and chlorambucil will be administered on Days 1-7 of each cycle at a dose of 10 mg/m\^2/day per oral (PO).

03

Conditions studied

  • Lymphocytic Leukemia, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • previously untreated participants with cluster of differentiation 20 (CD20) positive B-cell chronic lymphocytic leukemia;
  • participants with progressive Binet stage B, or C requiring therapy according to National Cancer Institute (NCI) criteria;
  • (ECOG) performance status \<=2.

Exclusion criteria

Exclusion Criteria:

  • previous treatment for Chronic Lymphocytic Leukaemia (CLL);
  • known concomitant hematological ;
  • transformation to aggressive B-cell malignancy;
  • history of severe cardiac disease;
  • known or anaphylactic reactions to murine antibodies.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Rituximab plus Chlorambucil

    Participants will receive combination therapy of rituximab plus chlorambucil for first 6 cycles and then chlorambucil alone for a maximum of 6 additional cycles.

    Drug: Rituximab · Drug: Chlorambucil

Interventions

  • 375mg/m\^2 IV on Day 1 of Cycle 1; 500mg/m\^2 on Day 1 of Cycles 2-6.

    Also known as: MabThera, Rituxan

  • 10 mg/m\^2/day PO on Days 1 to 7 of each cycle for a maximum of 12 cycles.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-Emergent Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 56 days from the beginning of the last treatment cycle that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs as well as non-serious AEs.

    Time frame: First administration of study treatment up to 56 days after the beginning of the last treatment cycle (up to 365 days)

Secondary outcomes

  1. Percentage of Participants With Best Overall Response (BOR) of Clinical CR or Confirmed CR

    Clinical CR was achieved if all of the following criteria were met: a)Absence of lymphadenopathy (LD) by physical examination (PE) and Computed Tomography (CT) scan (all lymph nodes less than \[\<\] 1.5 centimeters \[cm\] in diameter), b)No hepatomegaly (HM)/splenomegaly (SM) by PE/CT scan, c)Absence of B symptoms (unexplained fever greater than \[\>\] 38 degrees \[°\] Centigrade \[C\], drenching night sweats/\>10 percent \[%\] body weight loss in the last 6 months), d)Normal Complete Blood Count (CBC) (i. Leukocytes (Leuk) greater than or equal to \[≥\] 1.5×10\^9 per liter (/L), ii. Platelets (Plat) \>100×10\^9/L, and iii. Haemoglobin (Hb) \>11.0 grams per deciliter \[g/dL\]) and e)Once clinical, radiological and laboratory evaluations demonstrated CR, bone marrow (BM) biopsy and aspirate were performed 8 weeks later for confirmation; BM sample: normocellular for age, \<30% of the cells being lymphocytes (Lym) and lymphoid nodules (LN) absent was considered as a confirmed CR.

    Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)

  2. Percentage of Participants With BOR of Partial Response (PR)

    PR was achieved if all of the following criteria were met: a)≥50% decrease in Lym count from the baseline value, b)≥50% reduction in LD by CT scan, c)≥50% reduction in size of liver/spleen by PE/CT scan and at least 1 of the following for a minimum of 8 weeks: i. Leuk ≥1.5×10\^9/L or 50% improvement over baseline, ii. Plat \>100×10\^9/L or 50% improvement over baseline and iii. Hb \>11.0 g/dL or 50% improvement over baseline without transfusion. Participants who fulfilled criteria for CR with persistent anemia/thrombocytopenia were considered in PRs. CR was achieved if all of the criteria were fulfilled for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent.

    Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)

  3. Percentage of Participants With BOR of Nodular Partial Response (nPR)

    CR was achieved if all of the following criteria were met for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT scan, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. Participants with nPR were those who satisfied all of the CR criteria except for the BM, where LN could be identified histologically.

    Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)

  4. Percentage of Participants With BOR of Progressive Disease (PD)

    PD is considered if 1 of the following criteria is met: a)≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size (at least one ≥2 cm in diameter) or appearance of new lymph nodes/extranodal lesions, b)≥50% increase in the size of hepatosplenomegaly (HSM) as determined by PE/CT scan; appearance of palpable HM/SM that was not previously present, c)≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, d)Transformation to a more aggressive histology. Symptomatic deterioration (evident in clinical symptoms but not supported by tumor assessments), in such cases, the determination of clinical progression was based on symptomatic deterioration.

    Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)

  5. Percentage of Participants With BOR of Stable Disease (SD)

    Participants without CR/PR or PD were considered having a tumor response of SD. CR: a) Absence of LD by PE and CT, b) No HM/SM by PE/CT, c) Absence of B symptoms, d) Normal CBC, and e) BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PR: a) ≥50% decrease in Lym count from baseline, b) ≥50% reduction in LD, c) ≥50% reduction in size of liver/spleen by PE/CT and ≥1 of the following for at least 8 weeks: i. Leuk ≥1.5×10\^9/L or 50% improvement over baseline, ii. Plat \>100×10\^9/L or 50% improvement over baseline and iii. Hb \>11.0 g/dL or 50% improvement over baseline without transfusion. PD: a) ≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size or appearance of new lymph nodes/extranodal lesions, or b) ≥50% increase in the size of HSM; new appearance of palpable HM/SM, or c) ≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, or d) Transformation to a more aggressive histology.

    Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)

  6. Percentage of Participants With Objective Response (CR or PR)

    Objective response was defined as a tumor response of CR or PR. CR was achieved if all of the criteria were met for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT scan, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PR was achieved if all of the criteria were met: a)≥50% decrease in Lymp count from the baseline value, b)≥50% reduction in LD by CT scan, c)≥50% reduction in size of liver/spleen by PE/CT scan and at least 1 of the following for a minimum of 8 weeks: i. Leuk ≥1.5×10\^9/L or 50% improvement over baseline, ii. Plat \>100×10\^9/L or 50% improvement over baseline and iii. Hb \>11.0 g/dL or 50% improvement over baseline without transfusion. Participants who fulfilled criteria for CR with persistent anemia/thrombocytopenia were considered PRs.

    Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)

  7. Percentage of Participant With Disease Progression or Death

    PD is considered if 1 of the following criteria is met: a)≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size (at least one ≥2 cm in diameter) or appearance of new lymph nodes/extranodal lesions, b)≥50% increase in the size of HSM as determined by PE/CT scan; appearance of palpable HM/SM that was not previously present, c)≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, d)Transformation to a more aggressive histology. Symptomatic deterioration (evident in clinical symptoms but not supported by tumor assessments), in such cases, the determination of clinical progression was based on symptomatic deterioration.

    Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)

  8. Progression Free Survival (PFS) Time

    PFS was defined as the interval (in days) from trial treatment start date to earlier of the date of first tumor response assessment of PD or date of death by any cause. Participants who experienced none of these events or who were lost to follow-up at the time of analysis were censored on last date when they were assessed for tumor response. PD is considered if 1 of the following criteria is met: a)≥50% increase in sum of products of ≥2 lymph nodes compared to their smallest size (at least one ≥2 cm in diameter) or appearance of new lymph nodes/extranodal lesions, b)≥50% increase in the size of HSM as determined by PE/CT; appearance of palpable HM/SM that was not previously present, c)≥50% increase in the number of circulating Lym to ≥5×10\^9/L, d)Transformation to a more aggressive histology. Symptomatic deterioration (evident in clinical symptoms but not supported by tumor assessments), in such cases, the determination of clinical progression was based on symptomatic deterioration.

    Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)

  9. Disease Free Survival (DFS) Time

    DFS time was defined as interval (in days) from first tumor response of CR to date of first tumor response of PD, or date of death by any cause. Participants who experienced none of these events or who were lost to follow-up at the time of analysis were censored on last date when they were assessed for tumor response. CR: a) Absence of LD by PE and CT, b) No HM/SM by PE/CT, c) Absence of B symptoms, d) Normal CBC, and e) BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PD: a) ≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size or appearance of new lymph nodes/extranodal lesions, or b) ≥50% increase in the size of HSM; new appearance of palpable HM/SM, or c) ≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, or d) Transformation to a more aggressive histology.

    Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)

  10. Duration of Response (DoR)

    DoR: defined as interval (in days) from first tumor response (of CR/PR/nPR) to earlier of date of PD/death. Participants without PD/death or who were lost to follow-up were censored. CR: a)Absence of LD by PE and CT, b)No HM/SM by PE/CT, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PR: a)≥50% decrease in Lym count from baseline value, b)≥50% reduction in LD, c)≥50% reduction in size of liver/spleen by PE/CT scan and d)Leuk, Plat and Hb ≥1.5×10\^9/L, \>100×10\^9/L and \>11.0 g/dL, respectively or 50% improvement (of all the 3) over baseline value. nPR: participants who satisfied all of CR criteria except for BM, where LN could be identified. PD: a)≥50% increase in sum of the products of ≥2 lymph nodes or appearance of new lymph nodes/extranodal lesions, or b)≥50% increase in size of HSM; new appearance of palpable HM/SM, or c)≥50% increase in number of Lym, or d)Transformation to a more aggressive histology.

    Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)

  11. Percentage of Participants Who Died

    Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)

  12. Overall Survival (OS) Time

    This was defined as the interval (number of days) from the trial treatment start date to the date of death by any cause. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment.

    Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)

  13. Percentage of Participants Who Achieved Minimal Residual Disease (MRD) Negativity

    MRD negativity was defined by the absence of tumor cells in bone marrow, using 4-color flow cytometry. MRD was assessed in participants with a confirmed CR. CR was achieved if all of the following criteria were met for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT scan, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent.

    Time frame: Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)

  14. Mean Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Scores

    EORTC QLQ-C30: included global health status (GHS)/quality of life (QOL), functional scales (physical, role, cognitive, emotional, and social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulties). Most questions used a 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used a 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores were averaged and transformed to 0-100 scale; a higher score for Global Qol/functional scales=better level of QoL/functioning, or a higher score for symptom scale=greater degree of symptoms.

    Time frame: Baseline, Day 1 of Cycles 5 and 11, end of follow-up (FU) (24 month [m] FU visit, up to approximately 3 years)

07

Results

Posted Apr 6, 2016

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneRituximab + Chlorambucil
Started100
Completed51
Not completed49
Withdrew: Adverse event/serious adverse event25
Withdrew: Physician decision15
Withdrew: Disease progression3
Withdrew: Protocol violation1
Withdrew: Other5
Follow-up Period
Participant flow — Follow-up Period
MilestoneRituximab + Chlorambucil
Started98
Completed33
Not completed65
Withdrew: Adverse event/serious adverse event1
Withdrew: Disease progression57
Withdrew: Lost to follow-up1
Withdrew: Other6

Outcome measures

PrimaryPercentage of Participants With Treatment-Emergent Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious AE (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 56 days from the beginning of the last treatment cycle that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs as well as non-serious AEs.

Time frame:
First administration of study treatment up to 56 days after the beginning of the last treatment cycle (up to 365 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (AEs)
percentage of participantsRituximab + Chlorambucil
Percentage of Participants With Treatment-Emergent Adverse Events (AEs)99
SecondaryPercentage of Participants With Best Overall Response (BOR) of Clinical CR or Confirmed CR

Clinical CR was achieved if all of the following criteria were met: a)Absence of lymphadenopathy (LD) by physical examination (PE) and Computed Tomography (CT) scan (all lymph nodes less than \[\<\] 1.5 centimeters \[cm\] in diameter), b)No hepatomegaly (HM)/splenomegaly (SM) by PE/CT scan, c)Absence of B symptoms (unexplained fever greater than \[\>\] 38 degrees \[°\] Centigrade \[C\], drenching night sweats/\>10 percent \[%\] body weight loss in the last 6 months), d)Normal Complete Blood Count (CBC) (i. Leukocytes (Leuk) greater than or equal to \[≥\] 1.5×10\^9 per liter (/L), ii. Platelets (Plat) \>100×10\^9/L, and iii. Haemoglobin (Hb) \>11.0 grams per deciliter \[g/dL\]) and e)Once clinical, radiological and laboratory evaluations demonstrated CR, bone marrow (BM) biopsy and aspirate were performed 8 weeks later for confirmation; BM sample: normocellular for age, \<30% of the cells being lymphocytes (Lym) and lymphoid nodules (LN) absent was considered as a confirmed CR.

Time frame:
Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response (BOR) of Clinical CR or Confirmed CR
percentage of participantsRituximab + Chlorambucil
Clinical CR37.0
Confirmed CR10.0
Clinical CR or Confirmed CR47.0
SecondaryPercentage of Participants With BOR of Partial Response (PR)

PR was achieved if all of the following criteria were met: a)≥50% decrease in Lym count from the baseline value, b)≥50% reduction in LD by CT scan, c)≥50% reduction in size of liver/spleen by PE/CT scan and at least 1 of the following for a minimum of 8 weeks: i. Leuk ≥1.5×10\^9/L or 50% improvement over baseline, ii. Plat \>100×10\^9/L or 50% improvement over baseline and iii. Hb \>11.0 g/dL or 50% improvement over baseline without transfusion. Participants who fulfilled criteria for CR with persistent anemia/thrombocytopenia were considered in PRs. CR was achieved if all of the criteria were fulfilled for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent.

Time frame:
Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With BOR of Partial Response (PR)
percentage of participantsRituximab + Chlorambucil
Percentage of Participants With BOR of Partial Response (PR)68.0
SecondaryPercentage of Participants With BOR of Nodular Partial Response (nPR)

CR was achieved if all of the following criteria were met for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT scan, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. Participants with nPR were those who satisfied all of the CR criteria except for the BM, where LN could be identified histologically.

Time frame:
Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With BOR of Nodular Partial Response (nPR)
percentage of participantsRituximab + Chlorambucil
Percentage of Participants With BOR of Nodular Partial Response (nPR)6.0
SecondaryPercentage of Participants With BOR of Progressive Disease (PD)

PD is considered if 1 of the following criteria is met: a)≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size (at least one ≥2 cm in diameter) or appearance of new lymph nodes/extranodal lesions, b)≥50% increase in the size of hepatosplenomegaly (HSM) as determined by PE/CT scan; appearance of palpable HM/SM that was not previously present, c)≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, d)Transformation to a more aggressive histology. Symptomatic deterioration (evident in clinical symptoms but not supported by tumor assessments), in such cases, the determination of clinical progression was based on symptomatic deterioration.

Time frame:
Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With BOR of Progressive Disease (PD)
percentage of participantsRituximab + Chlorambucil
Percentage of Participants With BOR of Progressive Disease (PD)4.0
SecondaryPercentage of Participants With BOR of Stable Disease (SD)

Participants without CR/PR or PD were considered having a tumor response of SD. CR: a) Absence of LD by PE and CT, b) No HM/SM by PE/CT, c) Absence of B symptoms, d) Normal CBC, and e) BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PR: a) ≥50% decrease in Lym count from baseline, b) ≥50% reduction in LD, c) ≥50% reduction in size of liver/spleen by PE/CT and ≥1 of the following for at least 8 weeks: i. Leuk ≥1.5×10\^9/L or 50% improvement over baseline, ii. Plat \>100×10\^9/L or 50% improvement over baseline and iii. Hb \>11.0 g/dL or 50% improvement over baseline without transfusion. PD: a) ≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size or appearance of new lymph nodes/extranodal lesions, or b) ≥50% increase in the size of HSM; new appearance of palpable HM/SM, or c) ≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, or d) Transformation to a more aggressive histology.

Time frame:
Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With BOR of Stable Disease (SD)
percentage of participantsRituximab + Chlorambucil
Percentage of Participants With BOR of Stable Disease (SD)11.0
SecondaryPercentage of Participants With Objective Response (CR or PR)

Objective response was defined as a tumor response of CR or PR. CR was achieved if all of the criteria were met for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT scan, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PR was achieved if all of the criteria were met: a)≥50% decrease in Lymp count from the baseline value, b)≥50% reduction in LD by CT scan, c)≥50% reduction in size of liver/spleen by PE/CT scan and at least 1 of the following for a minimum of 8 weeks: i. Leuk ≥1.5×10\^9/L or 50% improvement over baseline, ii. Plat \>100×10\^9/L or 50% improvement over baseline and iii. Hb \>11.0 g/dL or 50% improvement over baseline without transfusion. Participants who fulfilled criteria for CR with persistent anemia/thrombocytopenia were considered PRs.

Time frame:
Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (CR or PR)
percentage of participantsRituximab + Chlorambucil
Percentage of Participants With Objective Response (CR or PR)84.0 (75.3 to 90.6)
SecondaryPercentage of Participant With Disease Progression or Death

PD is considered if 1 of the following criteria is met: a)≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size (at least one ≥2 cm in diameter) or appearance of new lymph nodes/extranodal lesions, b)≥50% increase in the size of HSM as determined by PE/CT scan; appearance of palpable HM/SM that was not previously present, c)≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, d)Transformation to a more aggressive histology. Symptomatic deterioration (evident in clinical symptoms but not supported by tumor assessments), in such cases, the determination of clinical progression was based on symptomatic deterioration.

Time frame:
Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participant With Disease Progression or Death
percentage of participantsRituximab + Chlorambucil
Percentage of Participant With Disease Progression or Death68.0
SecondaryProgression Free Survival (PFS) Time

PFS was defined as the interval (in days) from trial treatment start date to earlier of the date of first tumor response assessment of PD or date of death by any cause. Participants who experienced none of these events or who were lost to follow-up at the time of analysis were censored on last date when they were assessed for tumor response. PD is considered if 1 of the following criteria is met: a)≥50% increase in sum of products of ≥2 lymph nodes compared to their smallest size (at least one ≥2 cm in diameter) or appearance of new lymph nodes/extranodal lesions, b)≥50% increase in the size of HSM as determined by PE/CT; appearance of palpable HM/SM that was not previously present, c)≥50% increase in the number of circulating Lym to ≥5×10\^9/L, d)Transformation to a more aggressive histology. Symptomatic deterioration (evident in clinical symptoms but not supported by tumor assessments), in such cases, the determination of clinical progression was based on symptomatic deterioration.

Time frame:
Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Reported as:
Median · days
Progression Free Survival (PFS) Time
daysRituximab + Chlorambucil
Progression Free Survival (PFS) Time716.5 (500.0 to 784.0)
SecondaryDisease Free Survival (DFS) Time

DFS time was defined as interval (in days) from first tumor response of CR to date of first tumor response of PD, or date of death by any cause. Participants who experienced none of these events or who were lost to follow-up at the time of analysis were censored on last date when they were assessed for tumor response. CR: a) Absence of LD by PE and CT, b) No HM/SM by PE/CT, c) Absence of B symptoms, d) Normal CBC, and e) BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PD: a) ≥50% increase in sum of the products of ≥2 lymph nodes compared to their smallest size or appearance of new lymph nodes/extranodal lesions, or b) ≥50% increase in the size of HSM; new appearance of palpable HM/SM, or c) ≥50% increase in the absolute number of circulating Lym to ≥5×10\^9/L, or d) Transformation to a more aggressive histology.

Time frame:
Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Reported as:
Median · days
Disease Free Survival (DFS) Time
daysRituximab + Chlorambucil
Disease Free Survival (DFS) Time855.0 (290.0 to 855.0)
SecondaryDuration of Response (DoR)

DoR: defined as interval (in days) from first tumor response (of CR/PR/nPR) to earlier of date of PD/death. Participants without PD/death or who were lost to follow-up were censored. CR: a)Absence of LD by PE and CT, b)No HM/SM by PE/CT, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent. PR: a)≥50% decrease in Lym count from baseline value, b)≥50% reduction in LD, c)≥50% reduction in size of liver/spleen by PE/CT scan and d)Leuk, Plat and Hb ≥1.5×10\^9/L, \>100×10\^9/L and \>11.0 g/dL, respectively or 50% improvement (of all the 3) over baseline value. nPR: participants who satisfied all of CR criteria except for BM, where LN could be identified. PD: a)≥50% increase in sum of the products of ≥2 lymph nodes or appearance of new lymph nodes/extranodal lesions, or b)≥50% increase in size of HSM; new appearance of palpable HM/SM, or c)≥50% increase in number of Lym, or d)Transformation to a more aggressive histology.

Time frame:
Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Reported as:
Median · days
Duration of Response (DoR)
daysRituximab + Chlorambucil
Duration of Response (DoR)645.0 (561.0 to 758.0)
SecondaryPercentage of Participants Who Died
Time frame:
Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died
percentage of participantsRituximab + Chlorambucil
Percentage of Participants Who Died15.0
SecondaryOverall Survival (OS) Time

This was defined as the interval (number of days) from the trial treatment start date to the date of death by any cause. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment.

Time frame:
Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Reported as:
Median · percentage of participants
Overall Survival (OS) Time
percentage of participantsRituximab + Chlorambucil
Overall Survival (OS) TimeNA (NA to NA)
SecondaryPercentage of Participants Who Achieved Minimal Residual Disease (MRD) Negativity

MRD negativity was defined by the absence of tumor cells in bone marrow, using 4-color flow cytometry. MRD was assessed in participants with a confirmed CR. CR was achieved if all of the following criteria were met for ≥8 weeks: a)Absence of LD by PE and CT scan, b)No HM/SM by PE/CT scan, c)Absence of B symptoms, d)Normal CBC, and e)BM biopsy: normocellular for age, \<30% of the cells being Lym and LN absent.

Time frame:
Baseline until disease progression or death up to approximately 2.5 years (assessed at Baseline, Cycle 4 Day 1, Day 1 of Cycles 7-12, and thereafter every 3 months up to approximately 2.5 years; cycle length = 28 days)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Minimal Residual Disease (MRD) Negativity
percentage of participantsRituximab + Chlorambucil
Percentage of Participants Who Achieved Minimal Residual Disease (MRD) Negativity0.0
SecondaryMean Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Scores

EORTC QLQ-C30: included global health status (GHS)/quality of life (QOL), functional scales (physical, role, cognitive, emotional, and social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulties). Most questions used a 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used a 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores were averaged and transformed to 0-100 scale; a higher score for Global Qol/functional scales=better level of QoL/functioning, or a higher score for symptom scale=greater degree of symptoms.

Time frame:
Baseline, Day 1 of Cycles 5 and 11, end of follow-up (FU) (24 month [m] FU visit, up to approximately 3 years)
Reported as:
Mean · units on scale
Mean Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Scores
units on scaleRituximab + Chlorambucil
GHS/QoL score-baseline (n=91)65.7 ± 21.8
CFB in GHS/QoL Score-Cycle 5 (n=59)6.4 ± 21.7
CFB in GHS/QoL Score-Cycle 11 (n=40)6.2 ± 16.9
CFB in GHS/QoL Score-24m FU (n=17)2.0 ± 15.2
Physical functioning score-baseline (n=91)77.0 ± 22.3
CFB in physical functioning score-Cycle 5 (n=59)1.0 ± 15.3
CFB in physical functioning score-Cycle 11 (n=40)3.4 ± 22.0
CFB in physical functioning score-24m FU (n=17)-2.0 ± 10.2
Role functioning score-baseline (n=91)73.4 ± 31.6
CFB in role functioning score-Cycle 5 (n=59)0.0 ± 28.9
CFB in role functioning score-Cycle 11 (n=40)3.8 ± 32.1
CFB in role functioning score-24m FU (n=17)3.9 ± 20.0
Emotional functioning score-baseline (n=91)82.5 ± 18.1
CFB in emotional functioning score-Cycle 5 (n=59)1.0 ± 16.5
CFB in emotional functioning score-Cycle 11 (n=40)-0.1 ± 18.1
CFB in emotional functioning score-24m FU (n=17)0.5 ± 17.3
Cognitive functioning score-baseline (n=91)84.1 ± 19.1
CFB in cognitive functioning score-Cycle 5 (n=59)-1.9 ± 15.4
CFB in cognitive functioning-Cycle 11 (n=40)-0.4 ± 18.8
CFB in cognitive functioning-24m FU (n=17)5.2 ± 18.0
Social functioning score-baseline (n=91)82.2 ± 24.2
CFB in social functioning score-Cycle 5 (n=59)2.5 ± 22.5
CFB in social functioning score-Cycle 11 (n=40)0.0 ± 27.9
CFB in social functioning score-at 24m FU (n=17)5.2 ± 19.9
Fatigue score-baseline (n=91)33.4 ± 25.7
CFB in fatigue score-Cycle 5 (n=59)-1.4 ± 24.9
CFB in fatigue score-Cycle 11 (n=40)-6.1 ± 27.7
CFB in fatigue score-24m FU (n=17)-5.6 ± 22.2
Nausea/vomiting score-baseline (n=91)6.2 ± 16.2
CFB in nausea/vomiting score-Cycle 5 (n=59)1.7 ± 20.9
CFB in nausea/vomiting score-Cycle 11 (n=40)0.4 ± 20.8
CFB in nausea/vomiting score-24m FU (n=17)-2.9 ± 8.8
Pain score-baseline (n=91)17.8 ± 27.0
CFB in pain score-Cycle 5 (n=59)-3.4 ± 28.8
CFB in pain score-Cycle 11 (n=40)-1.3 ± 33.2
CFB in pain score-24m FU (n=17)0.0 ± 31.2
Statistical analysis
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.029
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.027
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.602
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.631
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.339
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.440
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =1.000
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.465
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.431
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.650
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.980
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.906
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.381
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.886
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.264
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.424
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =1.000
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.312
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.664
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.170
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.318
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.536
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.900
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.188
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.370
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =0.813
  • Rituximab + Chlorambucil · t-test, 2 sided · p = =1.000

Adverse events

Collected over First administration of study treatment up to 56 days after the beginning of the last treatment cycle (up to 365 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab + Chlorambucil—39/100 (39%)97/100 (97%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventRituximab + Chlorambucil
Febrile neutropeniaBlood and lymphatic system disorders5/100
Neutropenic sepsisInfections and infestations4/100
Infusion related reactionGeneral disorders3/100
PneumoniaInfections and infestations2/100
PyrexiaGeneral disorders2/100
VomitingGastrointestinal disorders2/100
Back painMusculoskeletal and connective tissue disorders2/100
Joint swellingMusculoskeletal and connective tissue disorders2/100
Cytokine release syndromeImmune system disorders2/100
Anal infectionInfections and infestations1/100
Most frequent other events
Showing 10 of 45
Most frequent other events
EventRituximab + Chlorambucil
NauseaGastrointestinal disorders51/100
LymphopeniaBlood and lymphatic system disorders41/100
NeutropeniaBlood and lymphatic system disorders41/100
FatigueGeneral disorders31/100
PyrexiaGeneral disorders27/100
LeukopeniaBlood and lymphatic system disorders23/100
VomitingGastrointestinal disorders22/100
AnaemiaBlood and lymphatic system disorders20/100
CoughRespiratory, thoracic and mediastinal disorders20/100
ThrombocytopeniaBlood and lymphatic system disorders19/100

Baseline characteristics

Full analysis set (FAS) comprised all participants recruited into the study and known to have received at least one dose of study treatment.

Age, Continuous
Age, Continuous(years)Rituximab + Chlorambucil
Mean69.5 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab + Chlorambucil
Female34
Male66
08

Study locations

12 sites
  • Birmingham, B9 5SS, United Kingdom
  • Bournemouth, BH7 7DW, United Kingdom
  • Cambridge, CB2 0QQ, United Kingdom
  • Canterbury, CT1 3NE, United Kingdom
  • Cottingham, HU16 5JQ, United Kingdom
  • Leeds, LS9 7TF, United Kingdom
  • Leicester, LE1 5WW, United Kingdom
  • Liverpool, L7 8XP, United Kingdom
  • London, EC1M 6BQ, United Kingdom
  • London, NW1 2PG, United Kingdom
  • Sutton, SM2 5PT, United Kingdom
  • Wakefield, WF1 4DG, United Kingdom
09

References and documents

Publications

  • Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE, Kennedy DB, Pettitt AR, Nathwani A, Varghese A, Cohen D, Rawstron A, Oertel S, Pocock CF. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol. 2014 Apr 20;32(12):1236-41. doi: 10.1200/JCO.2013.49.6547. Epub 2014 Mar 17. PubMed 24638012 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2007
First posted
Sep 19, 2007
Start
Nov 2007
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Results first posted
Apr 6, 2016
Last update
Apr 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00532129
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 19, 2007
Start date
Nov 2007
Primary completion
Apr 2012
Completion
Apr 2012
Results posted
Apr 6, 2016
Last update
Apr 6, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rituximab · Chlorambucil

Start the discussion